BioCentury | Mar 31, 2020
Product Development

Amarin set to appeal patent ruling that points way to generic competition for Vascepa

Amarin said it will appeal a judge’s patent decision that could blunt the rapid sales growth of cardiovascular drug Vascepa by removing a barrier for generic competition. The ruling, issued after market hours Monday, is...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BioCentury | May 11, 2019
Finance

Earnings on deck

Earnings on deck At least five profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 4Q; (B) Full-year EPS Company Date Pre/post mkt 1Q19 EPS est 1Q18 EPS Expected chg Eisai...
BC Extra | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
BC Extra | Feb 22, 2019
Company News

Indian generics champion Shah passes away

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, passed away Friday. The trade group's associate secretary-general, Archana Jatkar, confirmed the news to BioCentury. Known in the industry as DG Shah, the executive was CEO of...
BC Week In Review | Feb 22, 2019
Company News

Generic Suboxone products enter U.S. market

At least three companies have launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc (LSE:INDV). The generic Suboxone manufacturers include Alvogen Inc. (Pinebrook, N.J.), the Sandoz unit...
BioCentury | Jan 25, 2019
Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe; (B) Six-month EPS estimate; (C) Fiscal 3Q; (D)...
BC Week In Review | Nov 30, 2018
Company News

Dr. Reddy's gets green light to market opioid dependence generic

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) said on Nov. 20 that a U.S. federal court vacated a district court's preliminary decision that prohibited the company from selling its generic version of film Suboxone buprenorphine/naloxone sublingual from...
Items per page:
1 - 10 of 232
BioCentury | Mar 31, 2020
Product Development

Amarin set to appeal patent ruling that points way to generic competition for Vascepa

Amarin said it will appeal a judge’s patent decision that could blunt the rapid sales growth of cardiovascular drug Vascepa by removing a barrier for generic competition. The ruling, issued after market hours Monday, is...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BioCentury | May 11, 2019
Finance

Earnings on deck

Earnings on deck At least five profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 4Q; (B) Full-year EPS Company Date Pre/post mkt 1Q19 EPS est 1Q18 EPS Expected chg Eisai...
BC Extra | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
BC Extra | Feb 22, 2019
Company News

Indian generics champion Shah passes away

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, passed away Friday. The trade group's associate secretary-general, Archana Jatkar, confirmed the news to BioCentury. Known in the industry as DG Shah, the executive was CEO of...
BC Week In Review | Feb 22, 2019
Company News

Generic Suboxone products enter U.S. market

At least three companies have launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc (LSE:INDV). The generic Suboxone manufacturers include Alvogen Inc. (Pinebrook, N.J.), the Sandoz unit...
BioCentury | Jan 25, 2019
Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe; (B) Six-month EPS estimate; (C) Fiscal 3Q; (D)...
BC Week In Review | Nov 30, 2018
Company News

Dr. Reddy's gets green light to market opioid dependence generic

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) said on Nov. 20 that a U.S. federal court vacated a district court's preliminary decision that prohibited the company from selling its generic version of film Suboxone buprenorphine/naloxone sublingual from...
Items per page:
1 - 10 of 232